Back to search
FDAFDA · Food and drugs·Recall number Z-1924-2025

Azure S DR MRI SureScan, Product number W3DR01

Published June 18, 2025 · Recall initiated: April 29, 2025

Summary

FDA records medical device Class II recall Z-1924-2025, published June 18, 2025 and initiated April 29, 2025. Recalling firm: Medtronic, Inc.; Status: Ongoing; Reported quantity: 6; Lot: Serial numbers RNJ108800G, RNJ108808G, RNJ108810G UDI-DI 00763000956004 ***Updated 10/14/25*** Scope expanded to include implanted devices, serial numbers: RNJ108803G RNJ108804G RNJ108820G. Class II means possible temporary or medically reversible effects, or a remote probability of serious health consequences.

Status when published: Ongoing — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

Identified devices may experience sudden battery power failure without alarm, power supply power-on-resets, and interruption of therapy. Potential patient harms include insufficient pacing support leading to cardiac arrest, syncope, or hospitalization; or system revision (explant/replacement) leading to infection, hematoma, or temporary impairment.

What to do

Voluntary: Firm initiated · Letter

Get an email when a new FDA recall like this is published

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Manufacturer
Medtronic, Inc.
Distributor
International distribution of the country of UK. No US distribution.
Lot
Serial numbers RNJ108800G, RNJ108808G, RNJ108810G UDI-DI 00763000956004 ***Updated 10/14/25*** Scope expanded to include implanted devices, serial numbers: RNJ108803G RNJ108804G RNJ108820G
Risk classification
Class II
Area (FDA)
device
Country
United States

Related recalls

Questions about this recall

Was Azure S DR MRI SureScan, Product number W3DR01 recalled?

Yes. FDA published recall Z-1924-2025 on June 18, 2025. Reported hazard: Identified devices may experience sudden battery power failure without alarm, power supply power-on-resets, and interruption of therapy. Potential patient harms include insufficient pacing support leading to cardiac arrest, syncope, or hospitalization; or system revision (explant/replacement) leading to infection, hematoma, or temporary impairment.

What should I do if I have this product?

Voluntary: Firm initiated · Letter